CD22 and lymphoma: For example, upregulated proteins such as HLA-DRB1, CD22, CD74, and CD8A are consistent with established roles in lymphoid malignancies and oncogenic signaling, supporting prior studies identifying CD74 as a diagnostic and therapeutic target in lymphomas.33